Alle verbonden artikelen

PUBLISHED ERRATUM (2016): PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

Auteurs : Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, Denkert C, Schem C, Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart-Gebhart M, Von Minckwitz G, Baselga J
Jaar : 2018
Journal : Ann Oncol
Volume : 29
Pagina's : 2151

erratum :Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

Auteurs : Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L
Jaar : 2018
Journal : Ann Oncol
Volume : 29
Pagina's : 2152

18FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients.

Auteurs : de Cremoux P, Biard L, Poirot B, Bertheau P, Teixeira L, Lehmann-Che J, Bouhidel FA, Merlet P, Espié M, Resche-Rigon M, Sotiriou C, Groheux D
Jaar : 2018
Journal : Oncotarget
Volume : 9
Pagina's : 16343-16353

Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer.

Auteurs : Groheux D, Biard L, Lehmann-Che J, Teixeira L, Bouhidel FA, Poirot B, Bertheau P, Merlet P, Espié M, Resche-Rigon M, Sotiriou C, de Cremoux P
Jaar : 2018
Journal : Eur J Nucl Med Mol Imaging
Volume : 45(8)
Pagina's : 1279-1288

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.

Auteurs : Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, dHollander K, Pantel K
Jaar : 2018
Journal : J Natl Cancer Inst
Volume : 110(6)
Pagina's : 560-567

Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.

Auteurs : Zardavas D, Te Marvelde L, Milne RL, Fumagalli D, Fountzilas G, Kotoula V, Razis E, Papaxoinis G, Joensuu H, Moynahan ME, Hennessy BT, Bieche I, Saal LH, Stal O, Iacopetta B, Jensen JD, OToole S, Lopez-Knowles E, Barbaraeschi M, Noguchi S, Azim HA Jr, Lerma E, Bachelot T, Wang Q, Perez-Tenorio G, Can de Velde CJH, Rea DW, Sabine V, Bartlett JMS, Sotiriou C, Michiels S, Loi S
Jaar : 2018
Journal : J Clin Oncol
Volume : 36(10)
Pagina's : 981-990

Immuno-oncology-101: overview of major concepts and translational perspectives.

Auteurs : Allard B, Aspeslagh S, Garaud S, Dupont FA, Solinas C, Kok M, Routy B, Sotiriou C, Stagg J, Buisseret L
Jaar : 2018
Journal : Semin Cancer Biol
Volume : 52
Pagina's : 1-11

Immune Infiltration in Invasive Lobular Breast Cancer.

Auteurs : Desmedt C, Salgado R, Fornili M, Pruneri G, Van den Eynden G, Zoppoli G, Rothé F, Buisseret L, Garaud S, Willard-Gallo K, Brown D, Bareche Y, Rouas G, Galant C, Bertucci F, Loi S, Viale G, Di Leo A, Green AR, Ellis IO, Rakha EA, Larsimont D, Biganzoli E, Sotiriou C
Jaar : 2018
Journal : J Natl Cancer Inst
Volume : 110(7)
Pagina's : 768-776

Genomic hotspots but few recurrent fusion genes in breast cancer.

Auteurs : Fimereli D, Fumagalli D, Brown D, Gacquer D, Rothé F, Salgado R, Larsimont D, Sotiriou C, Detours V
Jaar : 2018
Journal : Genes Chromosomes Cancer
Volume : 57(7)
Pagina's : 331-338

Natural Anti-Estrogen Receptor Alpha Antibodies Able to Induce Estrogenic Responses in Breast Cancer Cells: Hypotheses Concerning Their Mechanisms of Action and Emergence.

Auteurs : Leclercq G
Jaar : 2018
Journal : Int J Mol Sci
Volume : 19

Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.

Auteurs : Bareche Y, Venet D, Ignatiadis M, Aftimos P, Piccart-Gebhart M, Rothé F, Sotiriou C
Jaar : 2018
Journal : Ann Oncol
Volume : 29(4)
Pagina's : 895-902

Response.

Auteurs : Lambertini M, Ameye L, Paesmans M, Peccatori FA, Azim HA Jr
Jaar : 2018
Journal : J Natl Cancer Inst
Volume : 110
Pagina's : 919-920

Network science in clinical trials: A patient-centered approach.

Auteurs : Manem VSK, Salgado R, Aftimos P, Sotiriou C, Haibe-Kains B
Jaar : 2018
Journal : Semin Cancer Biol
Volume : 52
Pagina's : 135-150

The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO.

Auteurs : Di Cosimo S, Campbell C, Azim HA Jr, Galli G, Bregni G, Curigliano G, Criscitiello C, Izquierdo M, de la Pena L, Fumagalli D, Fein L, Vinholes J, Ng WMJ, Colleoni M, Ferro A, Naume BJ, Patel A, Huober J, Piccart-Gebhart M, Baselga J, de Azambuja E
Jaar : 2018
Journal : Eur J Cancer
Volume : 89
Pagina's : 42-48

Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.

Auteurs : Buisseret L, Pommey S, Allard B, Garaud S, Bergeron M, Cousineau I, Ameye L, Bareche Y, Paesmans M, Crown JPA, Di Leo A, Loi S, Piccart-Gebhart M, Willard-Gallo K, Sotiriou C, Stagg J
Jaar : 2018
Journal : Ann Oncol
Volume : 29(4)
Pagina's : 1056-62

Evaluation of The Medical Board Exam in Portugal.

Auteurs : Marques TR, Laíns I, Martins MJ, Goiana-da-Silva F, Sampaio F, Pessanha I, Fernandes DH, Brandão M, Pinto Teixeira P, Oliveira Santos M, Silva JC, Ribeiro JC
Jaar : 2018
Journal : Acta Med Port
Volume : 31
Pagina's : 670-679

p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial.

Auteurs : Sonnenblick A, Salgado R, Brohée S, Zahavi T, Peretz T, Van den Eynden G, Rouas G, Salmon A, Francis PA, Di Leo A, Crown JPA, Viale G, Daly L, Javdan B, Fujisawa S, de Azambuja E, Ameye L, Piccart-Gebhart M, Bromberg JF, Sotiriou C
Jaar : 2018
Journal : Int J Oncol
Volume : 52(2)
Pagina's : 424-432

Marjolin's Ulcer with Axillary Lymph Node Metastasis.

Auteurs : Fernandes MG, Brandão M, Dias EM
Jaar : 2018
Journal : Acta Med Port
Volume : 31
Pagina's : 515

A gene signature to predict high tumour-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple negative breast cancer.

Auteurs : Criscitiello C, Bayar MA, Curigliano G, Symmans FW, Desmedt C, Bonnefoi H, Sinn B, Pruneri G, Vicier C, Pierga JY, Denkert C, Loibl S, Sotiriou C, Michiels S, André F
Jaar : 2018
Journal : Ann Oncol
Volume : 29(1)
Pagina's : 162-169

CDK4/6 inhibitors as neoadjuvant treatment in breast cancer - what can we learn?

Auteurs : Brandão M, Ignatiadis M
Jaar : 2018
Journal : Ann Oncol
Volume : 29(12)
Pagina's : 2274-2278